ChromaDex Announces New Clinical Trial to Investigate Niagen® & Milk Production Among Mothers in the Neonatal Intensive Care...
November 17 2020 - 06:35AM
Business Wire
Researchers to compare milk production among mothers of preterm
infants while receiving ChromaDex’s ingredient nicotinamide
riboside (Niagen®, or NR)
ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of
a human clinical trial of Niagen® (nicotinamide riboside, or NR)
investigating its potential to increase milk production among
preterm mothers. This new human trial follows promising preclinical
results which showed NR supplementation benefited both mother and
newborn animals. The double-blinded study will compare mothers’
levels of milk production and other markers of metabolism between
the experimental and control periods, respectively.
A study published in Cell Reports in 2019 reported that NR
supplementation significantly increased milk production among
rodent mothers with newborns, and promoted maternal weight loss
following delivery. NR was also found to increase levels of a
brain-growth promoting molecule called BDNF (brain-derived
neurotrophic factor) in the milk, which translated to lasting
improvements in coordination, strength, and learning capacity among
the offspring of NR-supplemented mothers.
These findings paved the way for the clinical trial on NR and
milk production just launched at the University of California,
Davis. The trial will enroll 32 participant mothers who deliver
preterm babies in the neonatal intensive care unit (NICU). These
mothers will either receive NR for 7 days, followed by placebo for
7 days, or the opposite combination (known as a cross-over
study).
“The lactation-promoting effects of NR that were observed in
rodents were encouraging, and we are eager to see if they can be
translated to human mothers and their children,” says Dr. Bruce
German, lead investigator, professor at the Department of Food
Science & Technology at the University of California, Davis,
and member of ChromaDex’s Scientific Advisory Board. “Adequate
breast milk production can be particularly life-saving among
mothers of preterm infants, and our team lead by Erin Ford hope to
generate promising data on this high-risk population.”
“This study will build upon the 11 published and over 40 ongoing
human trials involving NR,” said Dr. Andrew Shao, Senior Vice
President of ChromaDex Global Regulatory & Scientific Affairs.
“We are committed to expanding upon the many promising preclinical
and clinical findings to better understand NR’s myriad of health
benefits.”
ChromaDex has invested over $35 million in investigating and
marketing NR as Niagen, which has received regulatory acceptance in
the United States, Canada, the European Union, and Australia.
This new study is being conducted through the ChromaDex External
Research Program (CERP), which provides researchers with materials
and data to facilitate scientific innovation. CERP announced its
200th research agreement earlier this year.
For additional information on ChromaDex, please visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a science-based integrated nutraceutical
company devoted to improving the way people age. ChromaDex
scientists partner with leading universities and research
institutions worldwide to discover, develop and create solutions to
deliver the full potential of NAD and its impact on human health.
Its flagship ingredient, NIAGEN® nicotinamide riboside, sold
directly to consumers as TRU NIAGEN®, is backed with clinical and
scientific research, as well as extensive IP protection. TRU
NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a
website at www.chromadex.com to which ChromaDex regularly posts
copies of its press releases as well as additional and financial
information about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to whether Niagen® can
improve milk production in preterm mothers, whether Niagen® can
increase levels of a brain-growth promoting molecule called BDNF,
whether preclinical lactation-promoting effects of NR can be
translated to human mothers and their children, and the timing and
results of preclinical and clinical trials. Statements that are not
a description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects", "anticipates", "intends", "estimates",
"plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2019 as
amended, ChromaDex's Quarterly Reports on Form 10-Q and other
filings submitted by ChromaDex to the SEC, copies of which may be
obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201117005193/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of FP&A and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Feb 2024 to Mar 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2023 to Mar 2024